GO
Loading...

Abbott Laboratories

More

  • FDA approves weight-loss drug Contrave Thursday, 11 Sep 2014 | 6:53 AM ET

    Contrave joins two similar drugs from Arena Pharmaceuticals and Vivus Inc. which FDA approved in 2012 after a 13- year drought of new prescription weight-loss medicines. But sales of Vivus' Qsymia and Arena's Belviq have been far below expectations due to limited insurance coverage and high out-of-pocket costs for patients.

  • The FTC, which says AndroGel users paid hundreds of millions of dollars more than necessary because of the companies' actions, asked the U.S. District Court for the Eastern District of Pennsylvania to order AbbVie to refund users that money.

  • FTC sues AbbVie, Teva over generic AndroGel Monday, 8 Sep 2014 | 1:41 PM ET

    NEW YORK— The Federal Trade Commission is suing drugmakers AbbVie and Teva, saying they conspired to temporarily keep generic versions of AbbVie's low-testosterone drug AndroGel off the market.

  • SHANGHAI, Aug 25- The entanglement of H.J. Heinz Co. in China's latest food scare highlights a key concern for international and local firms- how to keep track of ingredients from diverse sources in a country where food supply tracing technologies are far from the norm.

  • WASHINGTON, Aug 7- An influential U.S. senator is encouraging the Internal Revenue Service to stamp out deals that allow companies to relocate their headquarters overseas in search of lower tax rates.

  • *Expects key drug launches in fourth quarter despite FDA delay. Aug 7- Political opposition to tax-inversion deals will not stop Mylan Inc's purchase of some non-U.S. businesses from Abbott Laboratories, Chief Executive Heather Bresch said, even as some companies have backed away from such tax arrangements.

  • *Cuts top end of FY earnings forecast to $3.45/ shr from $3.60/ shr. Aug 7- Mylan Inc shaved the top end of its full-year revenue and earnings forecasts, citing delays in approval from the U.S. Food and Drug Administration for key generic drugs that it plans to launch this year.

  • SHANGHAI/ HONG KONG, July 29- With green-tea flavoured toothpaste and pickled plum juice, an army of Chinese retailers is tapping local tastes to whittle away market share from global rivals that are banking their future growth on the world's second-largest consumer market.

  • Early movers: SBUX, V, AMZN, WMT, Z, XOM & more Friday, 25 Jul 2014 | 7:44 AM ET

    Some of the names on the move ahead of the open.

  • Did Congress prescribe Obamacare a 'poison pill?' Thursday, 24 Jul 2014 | 2:50 PM ET
    Felue Chang who is newly insured through the Affordable Care Act receives a checkup from Dr. Peria Del Pino-White at the South Broward Community Health Services clinic on April 15, 2014 in Hollywood, Florida.

    Surely Congress didn't mean to include a "poison pill" for the Affordable Care Act when it passed it, says law professor Tim Jost.

  • Who gets the last word on Obamacare? Wednesday, 23 Jul 2014 | 10:23 AM ET

    After a split ruling on Obamacare from the courts, who gets the last word? Law professor Dan Eaton weighs in.

  • LONDON/ MUMBAI, July 22- Indian generics firm Lupin, some U.S. drugmakers looking for a tax-saving deal in Europe and private equity funds are planning to bid for a range of older drugs being auctioned by GlaxoSmithKline, five sources familiar with the matter said.

  • Is patriotism a virtue in business? Friday, 18 Jul 2014 | 7:00 AM ET

    Do US firms have a duty to sacrifice their own interests for the broader good of the country?, asks law professor Dan Eaton.

  • Midday movers: Abbott, Northern Trust, Tesla & More Wednesday, 16 Jul 2014 | 1:02 PM ET
    Trader on the floor of the New York Stock Exchange.

    Some of Wednesday's midday movers:

  • *Sanofi mulls fate of 200 older drugs including Plavix. *Sanofi also held talks with TPG and Warburg Pincus. PARIS, July 16- Sanofi has held talks with Abbott Laboratories, Mylan and private equity firms over the possible sale of a 6.3 billion euro portfolio of mature drugs, according to an internal document seen by Reuters.

  • Sanofi mulls selling mature drug portfolio: Report Wednesday, 16 Jul 2014 | 8:39 AM ET

    Sanofi talked with Abbott Laboratories, Mylan and private equity firms over selling a portfolio of mature drugs, according to a document.

  • PARIS, July 16- Sanofi has held talks with Abbott Laboratories, Mylan and private equity firms over the possible sale of a 6.3 billion euro portfolio of mature drugs, according to an internal document seen by Reuters.

  • Jack Lew pushes for crackdown on tax inversions Wednesday, 16 Jul 2014 | 6:19 AM ET
    Jack Lew, U.S. Treasury Secretary.

    Treasury Secretary Jack Lew has urged Congress to crack down on merger deals in which companies seek to relocate overseas to cut US taxes.

  • Yellen? Here's what traders are really focused on Tuesday, 15 Jul 2014 | 6:51 PM ET
    Traders on the floor of the New York Stock Exchange.

    Stocks may respond more to earnings news than the Fed Wednesday, now that Fed Chair Janet Yellen's first day of testimony is out of the way.

  • How US drug firms plan to evade taxes Tuesday, 15 Jul 2014 | 5:35 AM ET

    Increasingly, drug makers and medical device companies have found a way to self-medicate when it comes to taxes and regulation.